Company Profile
Veracyte Stock Price, News & Catalysts
- Ticker:
- VCYT
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
44.19 USD (-4.02%)
Close
Last updated: October 1, 2026
3.81B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, VCYT closed down 4.02% at $44.19. No new same-company headline was identified in the current news window.
Company overview
Cancer Diagnostics Company
Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types.
Decipher Urologic Diagnostics
The Decipher franchise includes genomic classifiers for prostate and bladder cancer. These tests help clinicians assess disease aggressiveness and inform treatment intensity at key decision points.
Afirma Thyroid Testing
Afirma evaluates indeterminate thyroid nodules to help determine which patients may avoid diagnostic surgery and which may require further intervention. The platform also generates molecular information that can support treatment planning.
Breast and MRD Expansion
Prosigna estimates recurrence risk in early-stage hormone-receptor-positive breast cancer, while TrueMRD uses whole-genome sequencing to monitor molecular residual disease, initially in muscle-invasive bladder cancer.
Integrated Diagnostics Platform
Veracyte combines genomic and clinical data, bioinformatics, AI, laboratory operations, and evidence generation. The portfolio also includes programs in lung cancer and interstitial lung disease, creating opportunities across the diagnostic and treatment continuum.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Veracyte (VCYT)?
Veracyte (VCYT) most recently closed at 44.19 USD, a -4.02% move versus the previous session.
What is the market cap of Veracyte (VCYT)?
Veracyte currently has a market capitalization of 3.81B USD on BioPharmSignal.
What does Veracyte do?
Cancer Diagnostics Company Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types. Decipher Urologic Diagnostics The Decipher franchise includes genomic classifiers for prostate and bladder cancer. These tests help clinicians assess disease...
On which exchange is VCYT stock listed?
Veracyte (VCYT) is associated with NASDAQ, United States, MedTech.
What is Cancer?
Cancer Diagnostics Company Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types.
Which conditions is Veracyte targeting with Cancer?
Veracyte is associated with cancer therapeutics based on its company overview and current catalyst commentary.
What is Diagnostics?
Cancer Diagnostics Company Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types.
What is Veracyte?
Cancer Diagnostics Company Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types.